NO307464B1 - Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter - Google Patents

Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter

Info

Publication number: NO307464B1
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; compositions containing; medicaments; manufacture; same
Prior art date: 1993-10-15

Application number

NO943895A

Other languages

English (en)

Norwegian (no)

Other versions

NO943895L (no

NO943895D0 (no

Inventor

Jr Raymond Walter Kosley

Larry Davis

Veronica Taberna

Original Assignee

Hoechst Marion Roussel Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-14

Publication date

2000-04-10

1994-10-14 Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc

1994-10-14 Publication of NO943895D0 publication Critical patent/NO943895D0/no

1995-04-18 Publication of NO943895L publication Critical patent/NO943895L/no

2000-04-10 Publication of NO307464B1 publication Critical patent/NO307464B1/no

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical class O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
230000006949 cholinergic function Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000007074 memory dysfunction Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO943895A 1993-10-15 1994-10-14 Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter NO307464B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/137,444 US6316439B1 (en)	1993-10-15	1993-10-15	Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number	Publication Date
NO943895D0 NO943895D0 (no)	1994-10-14
NO943895L NO943895L (no)	1995-04-18
NO307464B1 true NO307464B1 (no)	2000-04-10

Family

ID=22477461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943895A NO307464B1 (no)	1993-10-15	1994-10-14	Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter

Country Status (23)

Country	Link
US (1)	US6316439B1 (de)
EP (1)	EP0649846B1 (de)
JP (1)	JP2664343B2 (de)
KR (1)	KR100227957B1 (de)
CN (1)	CN1039910C (de)
AT (1)	ATE211474T1 (de)
AU (1)	AU696170B2 (de)
CA (1)	CA2118172C (de)
CZ (1)	CZ283731B6 (de)
DE (1)	DE69429570T2 (de)
DK (1)	DK0649846T3 (de)
EG (1)	EG20726A (de)
ES (1)	ES2170759T3 (de)
FI (1)	FI108722B (de)
IL (1)	IL111275A (de)
NO (1)	NO307464B1 (de)
NZ (1)	NZ264682A (de)
PL (1)	PL177549B1 (de)
PT (1)	PT649846E (de)
RO (1)	RO114134B1 (de)
RU (1)	RU2109743C1 (de)
TW (1)	TW289754B (de)
ZA (1)	ZA948061B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT403803B (de)	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU780012B2 (en) *	1999-12-10	2005-02-24	Bonnie Davis	Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN101100472A (zh) *	2001-04-30	2008-01-09	美国拜尔公司	4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
US20030162770A1 (en) *	2002-02-22	2003-08-28	Davis Bonnie M.	Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) *	2002-05-21	2004-12-16	Nastech Pharmaceutical Company Inc.	Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
CA2552114A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Solid dosage formulations of galantamine
US20050191349A1 (en) *	2003-12-31	2005-09-01	Garth Boehm	Galantamine formulations
EP1779867A4 (de) *	2004-07-01	2009-12-02	Eisai R&D Man Co Ltd	Mittel zur förderung der nervenreveneration
EP2425846A1 (de) *	2004-12-23	2012-03-07	Voyager Pharmaceutical Corporation	Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit
DK1895994T3 (da) *	2005-05-13	2010-12-20	Alza Corp	Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
US20090253654A1 (en)	2005-09-22	2009-10-08	Galantos Pharma Gmbh	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) *	2005-09-23	2007-03-29	Alza Corporation	Transdermal galantamine delivery system
EP2137192B8 (de)	2008-04-14	2014-06-11	Neurodyn Life Sciences Inc.	Galantaminderivate als Prodrug-Verbindungen zur Behandlung humaner Hirnerkrankungen
US20120184532A1 (en) *	2009-07-23	2012-07-19	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
AU2015258814B2 (en) *	2014-05-16	2018-04-05	Synaptec Development Llc	Clearance of amyloid ss
EP4029867A1 (de)	2021-01-13	2022-07-20	Alpha Cognition Inc.	Feste formen von galantaminbenzoat-gluconat
US12551491B1 (en) *	2025-07-23	2026-02-17	Alpha Cognition Inc.	Dosage regimens for benzgalantamine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL122665B1 (en)	1978-11-21	1982-08-31	Edinen Zentar Chim	Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en)	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) *	1987-05-04	2008-11-27	Bonnie Davis	Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl)	1988-02-12	1989-09-01	Stichting Biomedical Research	Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
DE69229781T2 (de)	1991-05-14	2000-01-05	Ernir Snorrason	Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5153193A (en)	1991-10-01	1992-10-06	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) *	1991-10-01	1993-07-27	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

1993
- 1993-10-15 US US08/137,444 patent/US6316439B1/en not_active Expired - Lifetime
1994
- 1994-10-10 ES ES94115961T patent/ES2170759T3/es not_active Expired - Lifetime
- 1994-10-10 AT AT94115961T patent/ATE211474T1/de active
- 1994-10-10 EP EP94115961A patent/EP0649846B1/de not_active Expired - Lifetime
- 1994-10-10 PT PT94115961T patent/PT649846E/pt unknown
- 1994-10-10 DE DE69429570T patent/DE69429570T2/de not_active Expired - Lifetime
- 1994-10-10 DK DK94115961T patent/DK0649846T3/da active
- 1994-10-13 FI FI944823A patent/FI108722B/fi not_active IP Right Cessation
- 1994-10-13 RU RU94036745A patent/RU2109743C1/ru active
- 1994-10-13 IL IL11127594A patent/IL111275A/xx not_active IP Right Cessation
- 1994-10-13 NZ NZ264682A patent/NZ264682A/en not_active IP Right Cessation
- 1994-10-14 TW TW083109527A patent/TW289754B/zh not_active IP Right Cessation
- 1994-10-14 KR KR1019940026305A patent/KR100227957B1/ko not_active Expired - Lifetime
- 1994-10-14 CZ CZ942545A patent/CZ283731B6/cs not_active IP Right Cessation
- 1994-10-14 PL PL94305457A patent/PL177549B1/pl unknown
- 1994-10-14 CN CN94117062A patent/CN1039910C/zh not_active Expired - Lifetime
- 1994-10-14 RO RO94-01670A patent/RO114134B1/ro unknown
- 1994-10-14 CA CA002118172A patent/CA2118172C/en not_active Expired - Lifetime
- 1994-10-14 ZA ZA948061A patent/ZA948061B/xx unknown
- 1994-10-14 AU AU75813/94A patent/AU696170B2/en not_active Expired
- 1994-10-14 NO NO943895A patent/NO307464B1/no not_active IP Right Cessation
- 1994-10-15 EG EG64694A patent/EG20726A/xx active
- 1994-10-17 JP JP6250777A patent/JP2664343B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ264682A (en)	1995-07-26
EP0649846A1 (de)	1995-04-26
RO114134B1 (ro)	1999-01-29
PT649846E (pt)	2002-06-28
RU2109743C1 (ru)	1998-04-27
KR100227957B1 (ko)	1999-11-01
FI944823L (fi)	1995-04-16
ES2170759T3 (es)	2002-08-16
US6316439B1 (en)	2001-11-13
AU696170B2 (en)	1998-09-03
RU94036745A (ru)	1996-12-10
CZ254594A3 (en)	1995-07-12
DE69429570T2 (de)	2002-08-29
TW289754B (de)	1996-11-01
ATE211474T1 (de)	2002-01-15
DK0649846T3 (da)	2002-04-15
ZA948061B (en)	1995-06-06
DE69429570D1 (de)	2002-02-07
CA2118172C (en)	2000-01-04
NO943895L (no)	1995-04-18
FI108722B (fi)	2002-03-15
EP0649846B1 (de)	2002-01-02
IL111275A0 (en)	1994-12-29
KR950011445A (ko)	1995-05-15
FI944823A0 (fi)	1994-10-13
AU7581394A (en)	1995-05-04
JP2664343B2 (ja)	1997-10-15
IL111275A (en)	2003-01-12
PL305457A1 (en)	1995-04-18
CN1039910C (zh)	1998-09-23
CZ283731B6 (cs)	1998-06-17
PL177549B1 (pl)	1999-12-31
NO943895D0 (no)	1994-10-14
EG20726A (en)	1999-12-29
CA2118172A1 (en)	1995-04-16
CN1108657A (zh)	1995-09-20
JPH07188239A (ja)	1995-07-25

Legal Events

Date	Code	Title	Description
2014-10-27	MK1K	Patent expired

Publication	Publication Date	Title
IL109526A0 (en)	1994-08-26	Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
BG104998A (en)	2001-07-31	Isothiazole derivatives useful as anticancer agents
NO943895D0 (no)	1994-10-14	Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
DE69716810D1 (de)	2002-12-12	2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ATE103812T1 (de)	1994-04-15	Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
RU94036448A (ru)	1996-09-10	Производные галантамина и фармацевтическая композиция
TW375615B (en)	1999-12-01	Galanthamine derivatives and their use as medicaments
DE69008142D1 (de)	1994-05-19	4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
PT992509E (pt)	2004-12-31	Novos derivados macrolidos
NZ222640A (en)	1990-10-26	Quinolinol derivatives and pharmaceutical compositions
FR2687154B1 (fr)	1995-05-12	Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
HUT70761A (en)	1995-10-30	Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
DE69329184D1 (de)	2000-09-14	Alkylsubstituierte heterocyclische Verbindungen
WO1996031208A3 (de)	1996-11-14	Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
WO2000008006A3 (en)	2000-08-03	Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
HUT45059A (en)	1988-05-30	Process for producing abeoergoline derivatives
PT889044E (pt)	2005-01-31	Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE243219T1 (de)	2003-07-15	9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin